
Opinion|Videos|September 17, 2024
Oral vs. Injectable HMAs: Patient Perspectives, Access, and IRA Impact
Medical experts discuss innovations and future directions in treatments for higher-risk MDSMedical experts offer patient perspectives on advantages and disadvantages of using oral HMAs vs injectable HMAs.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- From a patient’s perspective, what are some of the advantages and disadvantages of using oral hypomethylating agents (HMAs) vs injectable HMAs?
- How do you anticipate the Inflation Reduction Act’s out-of-pocket prescription drug cost cap will affect access to oral HMAs starting in 2025?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Elinzanetant Shows Consistent Efficacy, Safety, and Sleep Benefits Across Studies
2
Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Menopause: Regina Castaneda, MD
3
Cytokines Linked With Drug Resistance in Ovarian Cancer, but Underlying Mechanisms Remain Unclear
4
CHEST 2025 Highlights: Future of Respiratory Vaccines and the Impact of Federal Funding Cuts
5











































